IDH1 and glioblastoma: A separate study by Arita et al., encompassing 260 IDH-wt glioblastoma patients, validated in a larger cohort, suggested that patients with both MGMTp methylation and TERTp mutations exhibited the most favorable prognosis, followed by those with TERTp wt and MGMTp methylation [22].